Literature DB >> 24692784

Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.

Lilia C Fernández1, Rosa Mas1, Julio Fernández1, Sarahí Mendoza1, Rafael Gámez1, Balia Pardo1.   

Abstract

BACKGROUND: The etiology of benign prostatic hyperplasia (BPH) is not completely understood, but hormonal changes in aging men seem to be pivotal. Dihydrotestosterone, a potent, active metabolite of testosterone, is formed by the enzymatic action of prostate 5α-reductase and causes cell growth and hyperplasia. Consistent with this action, male sexual dysfunction has been clinically documented to be among the drug-related adverse events associated with 5α-reductase inhibitors. The lipidosterolic extract of saw palmetto (LESP) fruit (Serenoa repens) has been used to treat BPH. D-004, a lipid extract of Roystonea regia Royal palm fruit, has been found to prevent prostatic hyperplasia induced by testoste-rone in rodents and to competitively inhibit prostate 5α-reductase activity in vitro.
OBJECTIVE: The purpose of this study was to assess the effects of D-004 and LESP, administered as single or repeated doses, on the sexual activity in male rats.
METHODS: This controlled, experimental study was conducted at the Pharmacology Department, Centre of Natural Products, National Centre for Scientific Research, Havana City, Cuba. Adult male Wistar rats weighing 250 to 300 g were randomized into 5 groups: 2 groups treated orally with D-004 (400 and 800 mg/kg); 2 groups treated orally with LESP (400 and 800 mg/kg); and 1 control group orally administered a water vehicle. Sexual activity behavior (the number of mounts and intromissions, mount latency, and intromission latency) was assessed during 2 observation periods: 90 minutes after the initial dose and at the end of the 30-day treatment. Latency was defined as time elapsed between the first mount and intromission.
RESULTS: A total of 50 rats (mean [SD] age, 10 [3] weeks; mean [SD] weight, 295 [10] g) were included in the experiment. There were no significant difterences in the mean number of mounts, intromissions, mount latency, or intromission latency in the groups treated with single or repeated doses of D-004 or LESP (400 and 800 mg/kg) compared with the controls. There was also no between-group difterence in mating behavior among the active treatment groups. All rats survived up to study completion, with normal behavior (weight gain, food intake, daily observations, without any sign of toxicity). There were no observable adverse events during the study.
CONCLUSIONS: D-004 and LESP administered as a single dose or repeated doses for 30 days did not significantly affect male rat sexual activity behavior compared with a vehicle control group.

Entities:  

Keywords:  D-004; Roystonea regia; Serenoa repens; rat mating behavior; rat sexual activity; saw palmetto

Year:  2008        PMID: 24692784      PMCID: PMC3969950          DOI: 10.1016/j.curtheres.2008.01.002

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  46 in total

1.  Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.

Authors:  Fouad K Habib; Margaret Ross; Clement K H Ho; Valerie Lyons; Karen Chapman
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

Review 2.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

3.  Alpha 1-adrenoceptor subtypes in the human cardiovascular and urogenital systems.

Authors:  M C Michel; K Taguchi; R S Schäfers; T J Williams; D E Clarke; A P Ford
Journal:  Adv Pharmacol       Date:  1998

4.  Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study.

Authors:  Daisy Carbajal; Maria de Lourdes Arruzazabala; Más Rosa; Vivian Molina; Eduardo Rodríguez; Victor González
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

5.  In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.

Authors:  L Yohani Pérez; Roberto Menéndez; Rosa Má; Rosa M González
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

Review 6.  Psychopharmacology of male rat sexual behavior: modeling human sexual dysfunctions?

Authors:  B Olivier; J S W Chan; T Pattij; T R de Jong; R S Oosting; J G Veening; M D Waldinger
Journal:  Int J Impot Res       Date:  2006 Sep-Oct       Impact factor: 2.896

7.  [Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa repens "Pierre Fabre Medicament)].

Authors:  Iu G Aliaev; A Z Vinarov; K L Lokshin; L G Spivak
Journal:  Urologiia       Date:  2002 Jan-Feb

8.  Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.

Authors:  K E Willetts; M S Clements; S Champion; S Ehsman; J A Eden
Journal:  BJU Int       Date:  2003-08       Impact factor: 5.588

9.  Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.

Authors:  L Rhodes; R L Primka; C Berman; G Vergult; M Gabriel; M Pierre-Malice; B Gibelin
Journal:  Prostate       Date:  1993       Impact factor: 4.104

10.  [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].

Authors:  Frans Debruyne; Gary Koch; Peter Boyle; Fernando Calais Da Silva; Jay G Gillenwater; Freddie C Hamdy; Paul Perrin; Pierre Teillac; Remigio Vela-Navarrete; Jean-Pierre Raynaud
Journal:  Prog Urol       Date:  2002-06       Impact factor: 0.915

View more
  1 in total

1.  Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.

Authors:  Raúl Guzmán; Julio C Fernández; Manuel Pedroso; Lilia Fernández; José Illnait; Sarahí Mendoza; Ana T Quiala; Zunilda Rodríguez; Jilma Mena; Aylim Rodíguez; Marbelis Campos; Carlos Sánchez; Yanet Alvarez; Gladys Jiménez
Journal:  Ther Adv Urol       Date:  2019-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.